Clinical application and research progress of remimazolam / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
;
(12): 1444-1448, 2021.
Article
Dans Chinois
| WPRIM
| ID: wpr-1014935
ABSTRACT
Remimazolam is a new ultra-short-acting sedative, with rapid onset and recovery, metabolism independent of liver and kidney function, light respiratory inhibition, stable hemodynamics, long time application without accumulation. Carboxylic acid metabolites have no pharmacological effects, and can be rapidly reversed by antagonist flumazenil, which is expected to become a new choice of clinical sedative. In this paper, pharmacological characteristics and recent research progress of remimazolam are reviewed, which can provide reference for clinical safe drug use.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Chinese Journal of Clinical Pharmacology and Therapeutics
Année:
2021
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS